Statement re Issuance of Patent

PROTEOME SCIENCES plc PRESS RELEASE Issuance of European Stroke Patent 15th January 2007. Proteome Sciences plc is pleased to announce that it has received a notice of intention to grant (notice of allowance) of European Patent Application Number 00979665.7 entitled "Diagnostic Assay for Stroke". The claims of the patent relate to methods of diagnosing stroke by measuring the levels of heart fatty acid binding protein and/or brain fatty acid binding protein (FABP's), two of Proteome Sciences' proprietary biomarkers discovered in the blood of stroke patients. The presence of FABP's in the blood of patients suffering from stroke was discovered by scientists at the University of Geneva in collaboration with Proteome Sciences. The two parties have subsequently worked together to validate their utility for diagnosing and monitoring the progression of stroke. This has additionally resulted in the discovery of further protein biomarkers, all of which are subject to patent applications in the major patent jurisdictions including the US, Europe and the Far East, from which combinations of stroke markers will be used to make panels for the diagnosis and prognosis of stroke in blood. Proteome Sciences has previously announced four licensing agreements relating to its portfolio of stroke biomarkers. Its licensees continue to undertake their respective development programmes and the company looks forward to further progress with both existing and future licensees in 2007. Commenting on the issuance Christopher Pearce, Chief Executive of Proteome Sciences said: "The allowance of the European patent following issuance of the related US case on some of our earliest biomarkers is further validation of the patentability of proteomics biomarkers in the second largest economic market and underpins the value and importance of our extensive intellectual property portfolio in protein biomarkers. We anticipate the issuance of further patents relating to the FABP's in other territories and that our pending applications for the other stroke biomarkers will proceed to grant. Issued European and US patents relating to our stroke biomarkers will enhance the continuing licensing process and we expect that further of the major global players in clinical diagnostics will now want to include and develop our biomarkers as in vitro diagnostic tests." Ends Notes to editors: Proteome Sciences plc Proteome Sciences, a global leader in applied proteomics, uses high sensitivity proprietary technologies to detect differentially expressed proteins in diseases. The protein biomarkers discovered in body fluids or tissues are validated, developed and commercialised as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing. Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high sensitivity/high throughput proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology and diagnostic companies, to discover and exploit protein biomarkers. Sensitizer® chemical mass tags have been developed separately as a series of stand-alone reagents. For further information please visit www.proteomics.com . Enquiries: Proteome Sciences plc Dr. Ian Pike, Business Development Director Email: ian.pike@proteomics.com Christopher Pearce, Chief Executive Officer Email: christopher.pearce@proteomics.com Tel: +44 (0)1932 865065 Public Relations for Proteome Sciences IKON Associates Adrian Shaw Tel: +44 (0)1483 535102 Mobile: +44 (0)797 9900733 Email: adrian@ikonassociates.com